Trials / Completed
CompletedNCT01384422
Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
* Thirty six patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 or matching placebo for 4 weeks. * During the course of the study, patients will also be examined for any side effects that may occur, and the amount of GLPG0634 present in the blood as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG0634 |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2011-06-29
- Last updated
- 2012-08-15
Locations
1 site across 1 country: Moldova
Source: ClinicalTrials.gov record NCT01384422. Inclusion in this directory is not an endorsement.